🇺🇸 FDA
Patent

US 9676846

Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

granted A61KA61K2039/505

Quick answer

US patent 9676846 (Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/505